CNS Pharmaceuticals' Berubicin failed to demonstrate statistically significant superiority in overall survival compared to Lomustine in recurrent glioblastoma patients, but showed comparable clinical outcomes across multiple endpoints.
CNS Pharmaceuticals presented updated results from its pivotal study comparing Berubicin to Lomustine in recurrent glioblastoma (GBM) patients, showing comparable demographics between treatment arms.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.